Targeting integrin/CD49D/VLA-4 with natalizumab can inhibit adhesion of malignant B cells and sensitize them to chemoimmunotherapy

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	MRÁZ Marek ZENT C. CHURCH A. JELINEK D. POSPÍŠILOVÁ Šárka ANSELL S. NOVAK A. WITZIG T. NOWAKOWSKI G.
Year of publication	2010
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Related projects:	Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies